Insider Selling: Karyopharm Therapeutics major shareholder Sells 43,699 Shares of Stock (KPTI)
Karyopharm Therapeutics (NASDAQ:KPTI) major shareholder Marcin Czernik unloaded 43,699 shares of the stock on the open market in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $38.80, for a total transaction of $1,695,521.20. The sale was disclosed in a filing with the SEC, which is available at this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
A number of research firms have recently commented on KPTI. Analysts at Leerink Swann cut their price target on shares of Karyopharm Therapeutics from $63.00 to $60.00 in a research note on Friday, August 8th. Analysts at Oppenheimer downgraded shares of Karyopharm Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, July 7th. One analyst has rated the stock with a hold rating and two have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $52.67.
Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded down 4.73% on Thursday, hitting $36.06. The stock had a trading volume of 49,480 shares. Karyopharm Therapeutics has a 1-year low of $15.50 and a 1-year high of $47.98. The stock has a 50-day moving average of $36.29 and a 200-day moving average of $34.62. The company’s market cap is $1.178 billion.
Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings data on Thursday, August 7th. The company reported ($1.02) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.50) by $0.52. Analysts expect that Karyopharm Therapeutics will post $-2.19 EPS for the current fiscal year.
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.